Gail Fulde
Overview
Explore the profile of Gail Fulde including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
6
Citations
117
Followers
0
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Greer S, Chen J, Ogmundsdottir M, Ayala C, Lau B, Delacruz R, et al.
Sci Rep
. 2022 Jun;
12(1):10333.
PMID: 35725745
Autophagy is a housekeeping mechanism tasked with eliminating misfolded proteins and damaged organelles to maintain cellular homeostasis. Autophagy deficiency results in increased oxidative stress, DNA damage and chronic cellular injury....
2.
Perkins A, Haslem D, Goldsberry J, Shortt K, Sittig L, Raghunath S, et al.
Cancers (Basel)
. 2021 Nov;
13(22).
PMID: 34830767
Purpose: To accurately ascertain the frequency of pathogenic germline variants (PGVs) in a pan-cancer patient population with universal genetic testing and to assess the economic impact of receiving genetic testing...
3.
Barker T, Fulde G, Moulton B, Nadauld L, Rhodes T
Sci Rep
. 2020 May;
10(1):7535.
PMID: 32371869
Systemic inflammation is present during and serves as a diagnostic tool for cancer-associated cachexia and is detrimental to serum 25-hydroxyvitamin D (25(OH)D) concentrations in non-cancer conditions. The neutrophil-to-lymphocyte ratio (NLR)...
4.
Xia L, Van Hummelen P, Kubit M, Lee H, Bell J, Grimes S, et al.
Sci Rep
. 2020 Mar;
10(1):5009.
PMID: 32193467
DNA copy number aberrations (CNA) are frequently observed in colorectal cancers (CRC). There is an urgent need for CNA-based biomarkers in clinics,. n For Stage III CRC, if combined with...
5.
Haslem D, Chakravarty I, Fulde G, Gilbert H, Tudor B, Lin K, et al.
Oncotarget
. 2018 Mar;
9(15):12316-12322.
PMID: 29552312
The impact of precision oncology on guiding treatment decisions of late-stage cancer patients was previously studied in a retrospective analysis. However, the overall survival and costs were not previously evaluated....
6.
Haslem D, Van Norman S, Fulde G, Knighton A, Belnap T, Butler A, et al.
J Oncol Pract
. 2016 Sep;
13(2):e108-e119.
PMID: 27601506
Purpose: The advent of genomic diagnostic technologies such as next-generation sequencing has recently enabled the use of genomic information to guide targeted treatment in patients with cancer, an approach known...